Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTABARBITAL vs BUCET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Butabarbital is a barbiturate that acts as a central nervous system depressant. It enhances the activity of GABA, an inhibitory neurotransmitter, by binding to the GABA-A receptor and prolonging the opening of chloride ion channels, leading to neuronal hyperpolarization and reduced excitability.
Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.
Sedative,Hypnotic for short-term treatment of insomnia,Preoperative sedation
Management of mild to moderate pain,Reduction of fever
50-100 mg orally or intramuscularly 3-4 times daily; maximum 400 mg/day.
Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.
Terminal elimination half-life is 30-50 hours in adults, which may be prolonged in elderly or patients with hepatic impairment, leading to accumulation with repeated dosing.
2-4 hours (terminal); prolonged in renal impairment
Hepatic metabolism via cytochrome P450 enzymes (primarily CYP2C9 and CYP3A4); undergoes hydroxylation and glucuronidation; active metabolites include hydroxybutabarbital.
Bucetin: Hepatic metabolism via hydroxylation and glucuronidation. Acetaminophen: Hepatic metabolism via glucuronidation, sulfation, and CYP2E1-mediated oxidation to NAPQI.
Primarily renal, with approximately 60-80% of the dose eliminated as metabolites (mostly hydroxylated and conjugated) and less than 5% as unchanged drug. Minor biliary/fecal excretion occurs (<10%).
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Approximately 20-25% bound to plasma proteins, predominantly albumin.
~85% bound to albumin
Approximately 1.0 L/kg, indicating distribution throughout total body water and extensive tissue binding.
0.3-0.5 L/kg; distributes primarily into extracellular fluid
Oral bioavailability is nearly 100% (50-70% reported in some texts, but butabarbital is completely absorbed; first-pass metabolism is minimal).
Oral: 75-90%
GFR 10-50 m L/min: reduce dose by 25%; GFR <10 m L/min: reduce dose by 50%.
GFR 10-50 m L/min: 50% dose reduction; GFR <10 m L/min: avoid use.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Children 2-6 years: 25-50 mg orally 3-4 times daily; children 6-12 years: 50-100 mg orally 3-4 times daily; maximum 200 mg/day.
Children 6-12 years: 5 mg/kg/dose every 6 hours as needed; maximum 20 mg/kg/day.
Initiate at 25-50 mg orally 3 times daily; increase cautiously to avoid excessive sedation and falls, maximum 200 mg/day.
Start at lowest effective dose (12.5 mg every 6 hours); maximum 150 mg/day due to increased fall risk and renal impairment.
Butabarbital has no FDA boxed warning.
No FDA black box warnings for bucet. Acetaminophen component: Risk of severe liver injury at high doses or with alcohol use.
Risk of dependence, tolerance, and withdrawal symptoms upon discontinuation; respiratory depression, especially with high doses or in patients with respiratory compromise; CNS depression may impair ability to drive or operate machinery; concomitant use with other CNS depressants (e.g., alcohol, opioids) increases risk of profound sedation and respiratory depression; geriatric patients may be more sensitive to effects; use with caution in patients with hepatic or renal impairment.
Hepatotoxicity risk with acetaminophen overdose,Avoid alcohol use,Hypersensitivity reactions,Skin reactions (Stevens-Johnson syndrome)
Hypersensitivity to barbiturates; porphyria (can exacerbate); severe respiratory insufficiency; history of addiction to sedative-hypnotics; acute or chronic pain (may cause paradoxical excitement); pregnancy (especially third trimester) and lactation.
Severe hepatic impairment,Hypersensitivity to bucetin or acetaminophen
Grapefruit juice may decrease metabolism of butabarbital; avoid concurrent consumption. Alcohol increases CNS depression and should be avoided. No specific food restrictions otherwise.
No known food interactions. Avoid alcohol as it may increase risk of side effects like dizziness.
First trimester: Associated with increased risk of major congenital malformations, specifically oral clefts (relative risk ~2.0). Second/third trimester: Chronic use may lead to fetal dependence and withdrawal syndrome; neonatal respiratory depression if used near term; increased risk of neurobehavioral effects. Barbiturates cross the placenta rapidly.
FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Butabarbital is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.4–0.6. With therapeutic doses, infant serum levels are usually low; however, chronic high maternal doses may cause sedation or withdrawal in the nursing infant. Caution is recommended; alternate agents may be preferred if infant sedation occurs.
Contraindicated. Excreted in human milk; M/P ratio not established. Potential for serious adverse effects in nursing infant.
Pregnancy can alter butabarbital pharmacokinetics due to increased hepatic metabolism and volume of distribution. Serum concentrations may decrease; therapeutic drug monitoring is recommended if used chronically. Dose adjustments may be necessary to maintain efficacy, but due to risks, use is generally avoided. If used, start with lowest effective dose and monitor for clinical response and toxicity.
Avoid use during pregnancy. If unavoidable, reduce dose by 50% due to increased clearance and altered protein binding.
Butabarbital is a short-acting barbiturate with rapid onset. It is primarily used for sedation and insomnia but has high abuse potential. Avoid use in patients with porphyria, severe hepatic impairment, or respiratory insufficiency. Abrupt discontinuation after prolonged use may precipitate withdrawal including seizures. Barbiturates induce CYP3A4 and other hepatic enzymes, reducing efficacy of oral contraceptives, warfarin, and corticosteroids. Use with caution in elderly due to increased risk of falls and cognitive impairment.
Bucet (bupivacaine hydrochloride and epinephrine) is used for local anesthesia. Epinephrine prolongs anesthetic effect and reduces systemic absorption. Avoid in patients with severe hypertension, hyperthyroidism, or concurrent MAO inhibitors. Monitor for CNS and cardiac toxicity, especially with high doses. Epinephrine concentration is 1:200,000; check for allergy to sulfites (antioxidant).
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not stop taking suddenly as withdrawal reactions such as anxiety, tremors, or seizures can occur.,May cause drowsiness or dizziness; do not drive or operate machinery until you know how this medicine affects you.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, opioids) as they increase risk of severe sedation and respiratory depression.,Use effective contraception while taking this medication as it may reduce hormonal contraceptive effectiveness.,Store in a secure place away from children and others, as it can cause dependence and is habit-forming.
Do not drive or operate machinery until numbness subsides.,Avoid touching or scratching the numb area to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) or intravenous injection symptoms (rapid heart rate, anxiety, headache).,The numbness will wear off over several hours depending on the dose and site.
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"Butabarbital, a barbiturate, is a potent CNS depressant that acts primarily by potentiating GABA-A receptor activity. Metaxalone is a centrally acting muscle relaxant with sedative properties. Coadministration results in additive or synergistic CNS depression, leading to increased risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential coma or death, especially at higher doses or in vulnerable patients."
"Butabarbital, a barbiturate sedative-hypnotic, induces hepatic cytochrome P450 enzymes, particularly CYP3A4, which are responsible for metabolizing the atypical antipsychotic paliperidone. This induction decreases plasma concentrations of paliperidone, potentially reducing its therapeutic efficacy in treating schizophrenia or bipolar disorder. Concomitant use may lead to relapse of psychiatric symptoms or necessitate dose adjustments."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTABARBITAL vs BUCET, answered by our medical review team.
BUTABARBITAL is a Barbiturate that works by Butabarbital is a barbiturate that acts as a central nervous system depressant. It enhances the activity of GABA, an inhibitory neurotransmitter, by binding to the GABA-A receptor and prolonging the opening of chloride ion channels, leading to neuronal hyperpolarization and reduced excitability.. BUCET is a Barbiturate Combination Analgesic that works by Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTABARBITAL and BUCET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTABARBITAL is: 50-100 mg orally or intramuscularly 3-4 times daily; maximum 400 mg/day.. The standard adult dose of BUCET is: Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUTABARBITAL and BUCET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUTABARBITAL is classified as Category C. First trimester: Associated with increased risk of major congenital malformations, specifically oral clefts (relative risk ~2.0). Second/third trimester: Chronic use may lead to fe. BUCET is classified as Category C. FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arterio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.